Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
08
2022
revised:
06
07
2023
accepted:
22
07
2023
medline:
31
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Elevated neutrophil counts in blood, sputum, or lung have been associated with poor clinical outcomes and more severe disease in patients with type 2 asthma. In the phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add-on dupilumab 200 and 300 mg every 2 weeks compared with matched placebo significantly reduced severe asthma exacerbations and improved forced expiratory volume in 1 s (FEV Annualized severe exacerbation rates during the 52-week treatment period and least-squares mean change from baseline in FEV Dupilumab significantly reduced annualized severe exacerbation rates compared with placebo during the 52-week treatment period in patients with elevated type 2 biomarkers, irrespective of baseline neutrophil count ( Dupilumab treatment significantly reduced annualized severe exacerbation rates and improved lung function in patients with uncontrolled, moderate-to-severe, type 2 asthma, irrespective of baseline blood neutrophil count. This trial is registered with NCT02414854.
Identifiants
pubmed: 37901346
doi: 10.1155/2023/9943584
pmc: PMC10602700
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Biomarkers
0
dupilumab
420K487FSG
Banques de données
ClinicalTrials.gov
['NCT02414854']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9943584Informations de copyright
Copyright © 2023 Eugene R. Bleecker et al.
Déclaration de conflit d'intérêts
E. R. Bleecker reports clinical trials from AstraZeneca, Boehringer Ingelheim, Genentech, MedImmune, Novartis, Regeneron Pharmaceuticals Inc., and Sanofi Genzyme through his employer, Wake Forest School of Medicine and University of Arizona; and personal fees (paid consultant) from ALK-Abelló, AstraZeneca, GlaxoSmithKline, MedImmune, Novartis, Regeneron Pharmaceuticals Inc., Sanofi Genzyme, and Teva. R. A. Panettieri has no conflicts of interest to disclose. N. L. Lugogo has received clinical trial funding from AstraZeneca, Genentech, GlaxoSmithKline, and Sanofi; and is an advisory board member and consultant for AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva. J. Corren reports research grants (consultant) from AstraZeneca, Genentech, Novartis, Regeneron Pharmaceuticals Inc., and Sanofi; and speaker fees from AstraZeneca, Genentech, and Novartis. N. Daizadeh is a former employee of Sanofi and may hold stock and/or stock options in the company. J. A. Jacob-Nara, P. J. Rowe, T. J. Ferro, and C. N. Hansen are employees of Sanofi, and may hold stock and/or stock options in the company. Y. Deniz, A, Khodzhayev, and X. Soler are employees and shareholders of Regeneron Pharmaceuticals Inc.
Références
Lancet Respir Med. 2016 Jul;4(7):574-584
pubmed: 27283230
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1285-1294.e6
pubmed: 33049391
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8
pubmed: 24706856
J Allergy Clin Immunol. 2019 Jul;144(1):1-12
pubmed: 31277742
Front Physiol. 2018 Feb 20;9:113
pubmed: 29515456
Clin Chem. 2017 Apr;63(4):823-832
pubmed: 28209625
J Allergy Clin Immunol. 2007 May;119(5):1043-52; quiz 1053-4
pubmed: 17472810
J Allergy Clin Immunol. 2014 Jun;133(6):1557-63.e5
pubmed: 24332216
Am J Respir Crit Care Med. 2021 Apr 1;203(7):882-892
pubmed: 33545021
Clin Exp Allergy. 2021 Jan;51(1):39-48
pubmed: 32706916
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
J Allergy Clin Immunol. 2014 May;133(5):1280-8
pubmed: 24589344
J Allergy Clin Immunol. 2020 Jan;145(1):430-433
pubmed: 31513878
Respirology. 2006 Jan;11(1):54-61
pubmed: 16423202
Cell Commun Signal. 2019 Nov 14;17(1):147
pubmed: 31727175
J Clin Invest. 2000 Nov;106(9):1081-93
pubmed: 11067861
Am J Respir Crit Care Med. 2009 Sep 1;180(5):388-95
pubmed: 19483109
Am J Respir Crit Care Med. 2007 Apr 15;175(8):783-90
pubmed: 17204725
J Allergy Clin Immunol. 2010 May;125(5):1028-1036.e13
pubmed: 20398920
Lancet. 1999 Jun 26;353(9171):2213-4
pubmed: 10392993
Chest. 2012 Jul;142(1):86-93
pubmed: 22345378
Semin Immunol. 2016 Apr;28(2):137-45
pubmed: 27021499
Lancet Respir Med. 2016 Oct;4(10):797-806
pubmed: 27574788
Am J Respir Crit Care Med. 2021 Apr 1;203(7):809-821
pubmed: 33326352
OMICS. 2013 Apr;17(4):187-99
pubmed: 23438328
J Allergy Clin Immunol. 2020 Jul;146(1):222-226
pubmed: 32032631
Trends Immunol. 2017 Dec;38(12):942-954
pubmed: 28784414
N Engl J Med. 2019 May 23;380(21):2009-2019
pubmed: 31112384
Curr Opin Immunol. 2020 Oct;66:123-128
pubmed: 33160187
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52
pubmed: 24706858
Eur Respir J. 2016 Oct;48(4):1052-1062
pubmed: 27540019